Claims for Patent: 6,884,797

Summary for Patent: 6,884,797

Title:	Targeted oxidative therapeutic formulation
Abstract:	Pharmaceutical formulation, its method of preparation, and its use. The pharmaceutical formulation contains peroxidic species or reaction products resulting from oxidation of an alkene, such as geraniol, by an oxygen-containing oxidizing agent, such as ozone; a penetrating solvent, such as dimethyl sulfoxide; a dye containing a chelated metal, such as hematoporphyrin; and an aromatic redox compound, such as benzoquinone. The pharmaceutical formulation is used to treat horses infected with Sarcocystis protozoal infections.
Inventor(s):	Hofmann; Robert F. (Austin, TX)
Assignee:
Application Number:	09/823,252
Patent Claims:	1. A pharmaceutical formulation comprising: peroxidic species or reaction products resulting from oxidation of an alkene by an oxygen-containing oxidizing agent, wherein the alkene has less than about 35 carbons; a penetrating solvent; a dye containing a chelated divalent or trivalent metal; and an aromatic redox compound. 2. The pharmaceutical formulation of claim 1, wherein the alkene comprises an open-chain unsaturated hydrocarbon, a monocyclic unsaturated hydrocarbon, or a bicyclic unsaturated hydrocarbon. 3. The pharmaceutical formulation of claim 1, wherein the alkene comprises an open-chain unsaturated alcohol, a monocyclic unsaturated alcohol, or a bicyclic unsaturated alcohol. 4. The pharmaceutical formulation of claim 1, wherein the alkene is an hydroxyl-contaning alkene. 5. The pharmaceutical formulation of claim 1, wherein the alkene is in a liquid form, in a solution, or in a dispersion. 6. The pharmaceutical formulation of claim 1, wherein the alkene comprises an isoprenoid. 7. The pharmaceutical formulation of claim 6, wherein the isoprenoid comprises .alpha.-terpineol, citronellol, nerol, phytol, menthol, geraniol, geranylgeraniol, linalool, or famesol. 8. The pharmaceutical formulation of claim 6, wherein the isoprenoid comprises myricene, citrillene, citral, pinene, or limonene. 9. The pharmaceutical formulation of claim 1, wherein the alkene comprises fixed oil-, ester-, fatty acid-, or ether-containing olefin. 10. The pharmaceutical formulation of claim 1, wherein the oxygen-containing oxidizing agent comprises singlet oxygen, oxygen in its triplet state, superoxide anion, periodate, hydroxyl radical, peroxide, or oxygen bound to a transition element. 11. The pharmaceutical formulation of claim 1, wherein the oxygen-containing oxidizing agent comprises ozone. 12. The pharmaceutical formulation of claim 1, wherein the penetrating solvent is a liquid, micelle membrane, emollient, plasma, or vapor. 13. The pharmaceutical formulation of claim 1, wherein the penetrating solvent is dimethylsulfoxide. 14. The pharmaceutical formulation of claim 1, wherein the penetrating solvent is polyvinylpyrrolidine or a pH-buffered saline. 15. The pharmaceutical formulation of claim 1, wherein the penetrating solvent is aqueous solution, fats, sterols, lecithins, phosphatides, ethanol, propylene glycol, or methylsulfonylmethane. 16. The pharmaceutical formulation of claim 1, wherein the dye can be activated by an energy. 17. The pharmaceutical formulation of claim 1, wherein the dye comprises porphyrin or rose bengal. 18. The pharmaceutical formulation of claim 1, wherein the dye comprises chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, or fluorescein. 19. The pharmaceutical formulation of claim 16, wherein the energy comprises photon or electroporation pulse. 20. The pharmaceutical formulation of claim 13, wherein the energy comprises laser, ionizing radiation, phonon, electrical pulse, magnetic field, plasma pulse, gravitational pulse, or continuous flow excitation. 21. The pharmaceutical formulation of claim 1, wherein the metal comprises iron. 22. The pharmaceutical formulation of claim 1, wherein the metal comprises copper, manganese, tin, magnesium, or strontium. 23. The pharmaceutical formulation of claim 1, wherein the aromatic redox compound comprises benzoquinone or naphthoquinone. 24. The pharmaceutical formulation of claim 1 further comprising an electron donor. 25. The pharmaceutical formulation of claim 24, wherein the electron donor comprises ascorbic acid or a pharmaceutical salt thereof. 26. The pharmaceutical formulation of claim 24, wherein the electron donor comprises plasma, electrical current or germanium sesquioxide. 27. A pharmaceutical formulation comprising: peroxidic species or reaction products resulting from oxidation of a hydroxyl-containing alkene by a mixture of ozone and oxygen, wherein the hydroxyl-containing alkene has less than about 35 carbons; a penetrating solvent; a dye containing a chelated divalent or trivalent metal; and an aromatic redox compound. 28. The pharmaceutical formulation of claim 27, wherein the hydroxyl-containing alkene comprises an open-chain unsaturated alcohol, a monocyclic unsaturated alcohol, or a bicyclic unsaturated alcohol. 29. The pharmaceutical formulation of claim 27, wherein the hydroxyl-containing alkene is in a liquid form, in a solution, or in dispersion. 30. The pharmaceutical formulation of claim 27, wherein the hydroxyl-containing alkene comprises .alpha.-terpineol, citronellol, nerol, linalool, phytol, geraniol, perillyl alcohol, menthol, geranylgeraniol, or famesol. 31. The pharmaceutical formulation of claim 27, wherein the penetrating solvent is a liquid, micelle membrane, emollient, plasma, or vapor. 32. The pharmaceutical formulation of claim 27, wherein the penetrating solvent is dimethylsulfoxide. 33. The pharmaceutical formulation of claim 27, wherein the penetrating solvent is polyvinylpyrrolidine or a pH-buffered saline. 34. The pharmaceutical formulation of claim 27, wherein the penetrating solvent is aqueous solution, fats, sterols, lecithins, phosphatides, ethanol, propylene glycol, or methylsulfonylmethane. 35. The pharmaceutical formulation of claim 27, wherein the dye comprises porphyrin or rose bengal. 36. The pharmaceutical formulation of claim 27, wherein the dye comprises chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, or fluorescein. 37. The pharmaceutical formulation of claim 27, wherein the metal comprises iron. 38. The pharmaceutical formulation of claim 27, wherein the metal comprises copper, manganese, tin, magnesium, or strontium. 39. The pharmaceutical formulation of claim 27, wherein the aromatic redox compound comprises benzoquinone or naphthoquinone. 40. The pharmaceutical formulation of claim 27 further comprising an electron donor. 41. The pharmaceutical formulation of claim 40, wherein the electron donor comprises ascorbic acid or a pharmaceutical salt thereof. 42. The pharmaceutical formulation of claim 40, wherein the electron donor comprises plasma, electrical current or germanium sesquioxide. 43. A pharmaceutical formulation comprising: peroxidic species or reaction products resulting from oxidation of a hydroxyl-containing alkene by a mixture of ozone and oxygen, wherein the hydroxyl-containing comprises .alpha.-terpineol, citronellol, nerol, linalool, phytol, geraniol, perillyl alcohol, menthol, geranylgeraniol or farnesol; a penetrating solvent, wherein the penetrating solvent comprises dimethylsulfoxide, sterol, lecithin, propylene glycol, or methylsulfonylmethane; a dye containing a chelated divalent or trivalent metal, wherein the dye comprises porphyrin, rose bengal, chlorophyllin, hemin, corrins, texaphrin, methylene blue, hematoxylin, eosin, erythrosin, lactoflavin, anthracene dye, hypericin, methylcholanthrene, neutral red, or fluorescein; and an aromatic redox compound, wherein the redox compound comprises benzoquinone or naphthoquinone. 44. The pharmaceutical formulation of claim 43, wherein the metal comprises iron, copper, manganese, tin, or magnesium. 45. The pharmaceutical formulation of claim 43 further comprising an electron donor. 46. The pharmaceutical formulation of claim 45, wherein the electron donor comprises ascorbic acid or a pharmaceutical salt thereof. 47. The pharmaceutical formulation of claim 45, wherein the electron donor comprises plasma, electrical current or germanium sesquioxide.

Details for Patent 6,884,797

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Recordati Rare Diseases, Inc.	PANHEMATIN	hemin for injection	For Injection	101246	07/20/1983		2040-01-28